Small airway imaging phenotypes in biomass- and tobacco smoke-exposed patients with COPD by Fernandes, Lalita et al.
  
 University of Groningen
Small airway imaging phenotypes in biomass- and tobacco smoke-exposed patients with
COPD
Fernandes, Lalita; Gulati, Nandani; Fernandes, Yasmin; Mesquita, Anthony Menezes;
Sardessai, Mahesh; Lammers, Jan-Willem J; Mohamed Hoesein, Firdaus A; Ten Hacken,





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Fernandes, L., Gulati, N., Fernandes, Y., Mesquita, A. M., Sardessai, M., Lammers, J-W. J., ... Siddiqui, S.
(2017). Small airway imaging phenotypes in biomass- and tobacco smoke-exposed patients with COPD.
ERJ Open Research, 3(2). https://doi.org/10.1183/23120541.00124-2016
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-11-2019
Small airway imaging phenotypes in
biomass- and tobacco smoke-exposed
patients with COPD
To the Editor:
Chronic obstructive pulmonary disease (COPD) is currently the third most common cause of death,
worldwide [1]. Tobacco smoke (TS) is the main risk factor for COPD in developed countries, but biomass
smoke (BMS) exposure is the leading cause in developing countries, particularly in women [2].
Early studies evaluating BMS-induced changes in the lung parenchyma used high-resolution computed
tomography (CT), which demonstrated thickening of the interlobular septae, fibrotic bands, ground glass
appearance and emphysema. These findings suggest that BMS exposure is associated with pathological
disease in the small airways of lung [3], and support the notion of pathological damage to the small
airways in patients with BMS-exposed COPD.
Recent advances in image processing now allow accurate image registration approaches that provide
functional information about the small airways [4]. Parametric response mapping (PRM) is an imaging
tool that has been shown to individually quantify small airways disease and emphysema in COPD [5].
This is achieved through the spatial alignment of CT images acquired at functional residual capacity (FRC)
and total lung capacity (TLC) followed by classification of individual voxels.
We aimed to determine the degree of emphysematous, functional small airway and non-emphysematous
airflow obstruction from a cohort of BMS- and TS-exposed female COPD patients with matched levels of
spirometric airflow limitation. We hypothesised that BMS-exposed patients would demonstrate a distinct
profile of small airways disease when compared to TS exposed patients.
We performed a prospective observational study based in the respiratory hospital outpatient clinic of Goa
Medical College, Goa, India. The study was approved by the institutional ethics committee (IEC/CR/
GMC/2012/024), and all subjects gave informed consent. A total of 57 patients aged ⩾40 years, with stable
COPD, were enrolled between November 2012 and April 2014. From this cohort, all 17 BMS-exposed
female COPD patients were included in the study, and 2 were excluded for failed image registration. As
most Indian women are exposed to BMS and the prevalence of smoking among women is low, we did not
have women with exclusive TS-associated COPD. Accordingly, a comparator group of TS-exposed women
(N=20) was evaluated, taken from the TI Pharma cohort [6] from a secondary care COPD population in
the Netherlands. The comparator group was matched to the Goa cohort for age, sex, post-bronchodilator
forced expiratory volume in 1 s % predicted (FEV1 % pred) and FEV1/forced vital capacity (FVC).
COPD was diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD)
guidelines [7]. All patients underwent detailed COPD characterisation. Spirometry was performed
according to American Thoracic Society (ATS)/European Respiratory Society (ERS) 2005 guidelines [8].
Exposures were evaluated using the Burden of Obstructive Lung Disease (BOLD) Core and BOLD biomass
and fuel questionnaires [9]. Exposure to BMS was reported in hour-years, which are the product of the
average number of hours the patient has spent cooking daily and the number of years of cooking using
biomass fuel. The cumulative exposure to TS was quantified as pack-years.
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Computed tomography of the lung was performed using a Somatom Definition AS multi-detector CT
(MDCT) (Siemens Healthcare GmbH, Erlangen, Germany). We used a low-dose radiation protocol, with
140 kVp tube voltage and with the milli-amperes (mA) tube current set according to body mass index.
The lung was scanned in the supine position from apex to base in deep inspiration (total lung capacity)
and expiration (functional residual capacity). For the TI Pharma cohort, CT scans were performed using a
64-multidetector scanner (Somatom Definition, Siemens, Forchheim, Germany). Scans were performed at
full inspiration and expiration (near residual volume). Scanning was performed with 20 mA·s. The kV
setting was adjusted to weight. Acquired imaging data were reconstructed using a standard soft kernel
(B30f), with 1.0 mm slice thickness and 0.7 mm increment.
PRM is a unique quantitative assessment method for investigating COPD that, when applied to paired CT
images, allows quantification of emphysema and functional small airway disease. This analysis was
performed using Lung Density Analysis software (Imbio, Minneapolis, MN, USA). There are three
fundamental steps: inspiratory and expiratory image acquisition, image processing (which involves lung
parenchyma segmentation and co-registration of inspiratory and expiratory scans) and classification of
voxels in terms of Hounsfield values (HU), where green represents normal lung parenchyma [PRMNormal],
yellow is functional small airway disease [PRMfSAD] and red is emphysema [PRMEmph]. Voxels of lungs
with inspiration and expiration CT attenuation less than −950 HU and −856 HU, respectively, were
defined as emphysema, voxels greater than −950 HU on inspiration, but less than −865 HU on expiration
are areas of gas trapping due to functional small airway disease, and voxels with inspiration and expiration
greater than −950 HU and −856 HU, respectively, were classified as normal parenchyma.
Variables were expressed as mean and standard deviation or median and interquartile range. Mann–Whitney
U-test, t-tests and linear regression were applied. Statistical analysis was performed using the statistical
software package SPSS 23 (IBM Corp., Armonk, NY, USA).
Clinical and spirometry data were well matched: mean±SD age 60.60±5.28 and 64.20±7.97 years,
post-bronchodilator FEV1 61.42±27.02% and 62.33±20.27%, and FEV1/FVC 48.35±14.92 and 55.86±12.49,
in the TS- and BMS-exposed populations, respectively.
Figure 1 depicts typical PRM classification images in representative BMS-exposed and TS-exposed patients
with GOLD stage 3 COPD.
PRM analysis of CT images demonstrated that COPD patients with BMS exposure had similar healthy lung
voxels (49.95±14.11%) when compared to TS-exposed patients (43.50±13.5%), p=0.185. In addition, both
TS- and BMS-exposed patients had similar levels of PRMfSAD (33.41±8.33% versus 39.43±12.95%, p=0.11).
In contrast, TS-exposed patients had significantly more emphysema (i.e. PRMEmph) than BMS-exposed
patients; median 9.85% (2.40–16.34%) compared to 1.84% (0.69±3.72%) (p=0.001).
Stepwise linear regression identified that PRMEmph (model R2=0.607, β=−0.79; p=0.001) and PRMfSAD
(model R2=0.461, β=−0.70; p=0.003) were significant independent predictors of post bronchodilator
FEV1/FVC in TS- and BMS-exposed COPD patients, respectively.
We have identified, for the first time, that BMS-exposed COPD patients have a distinct pattern of small
airway disease characterised by functional small airways disease in the absence of significant emphysema. Our











FIGURE 1 Composite PRM image (PRM∑) in two exemplar patients with tobacco smoke (TS) exposure and
chronic obstructive pulmonary disease (COPD) (top left) and biomass smoke (BMS) exposure and COPD
(bottom left). The colours in the two-dimensional image (top and bottom left) and three-dimensional image
reconstructions (left to right) represent PRMNormal (normal healthy and deforming lung voxels; green),
PRMfSAD (functional small airways disease voxels; yellow) and PRMEmph (emphysema voxels; red).
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significant gas trapping in BMS-exposed COPD (via qualitative assessment) and significant emphysema in
TS-exposed COPD (via quantitative assessment). This latter report demonstrated, in two female cohorts, that
BMS exposure was preferentially associated with CT low-attenuation areas and gas trapping, in contrast to TS
exposure, which was associated with emphysema in a cohort of Mexican women. In contrast, we identified
functional small airways disease using image registration and PRM in both BMS- and TS-exposed females
within our Indian cohort. Our observations may suggest that the PRM imaging approach, which allows the
differentiation of voxels associated with gas trapping and low CT attenuation due to emphysema and small
airways dysfunction, is more specific for small airways disease than the approach in the CAMP et al. paper
[10]. Further validation of this concept comes from the observation that emphysema, which does not require
image registration for quantification, was associated only with TS exposure in both our cohorts.
Our observations suggest that the nature of small airways disease in COPD may be related to specific
prototypes of environmental/extrinsic exposures. In addition, our report suggests that spirometric airflow
obstruction may be differentially regulated by functional small airways disease and emphysema in BMS-
and TS-exposed patients, respectively.
Our report has a number of limitations, including the small sample size and ethnicity imbalance in the two
exposure groups. Due to the low prevalence of female smokers without BMS exposure in rural Indian female
communities, we identified a comparator population of Caucasians with TS-exposed COPD in the
Netherlands. Furthermore the impact of using FRC and near residual volume expiratory imaging in the Goa
and T1 Pharma cohorts, respectively, may have introduced bias into the imaging quantification. Additionally,
it is possible that differences in diet, lifestyle and environmental exposure between the two study cohorts may
have been attributable for some of the observed differences in quantitative PRM imaging features.
Nonetheless, we have shown for the first time that BMS-exposed COPD patients have a distinct pattern of
small airways disease when compared to TS-exposed patients. These observations now need to be validated
in larger population studies.
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